

1 **Causal associations of education, lifestyle behaviors, and cardiometabolic traits**
2 **with epigenetic age acceleration: a Mendelian randomization study**

3

4 Lijie Kong,^{1,2*} Chaojie Ye,^{1,2*} Yiying Wang,^{1,2} Jie Zheng,³ Shuangyuan Wang,^{1,2}
5 Hong Lin,^{1,2} Zhiyun Zhao,^{1,2} Mian Li,^{1,2} Yu Xu,^{1,2} Jieli Lu,^{1,2} Yuhong Chen,^{1,2} Min
6 Xu,^{1,2} Weiqing Wang,^{1,2} Guang Ning,^{1,2} Yufang Bi,^{1,2} Tiange Wang^{1,2}

7

8 *Lijie Kong and Chaojie Ye contributed equally as first authors.

9

10 **Author Affiliations:**

11 ¹Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine
12 and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of
13 Medicine, Shanghai, China;

14 ²Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory
15 for Endocrine and Metabolic Diseases of the National Health Commission of the PR
16 China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of
17 Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of
18 Medicine, Shanghai, China;

19 ³MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of
20 Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

21

22 **Correspondence:**

23 **Tiange Wang**, MD, PhD. Shanghai National Clinical Research Center for Endocrine
24 and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases,
25 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rujin 2nd

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Road, Shanghai, China. E-mail: wtg@live.cn. Phone number: 86-021-64370045.

27 **Key Points**

- 28 • Genetically predicted higher educational attainment is the strongest protective
29 factor for both GrimAgeAccel and PhenoAgeAccel, independent of causal
30 lifestyle and cardiometabolic risk factors.
- 31 • Smoking is the leading causal lifestyle risk factor for GrimAgeAccel or
32 PhenoAgeAccel, followed by alcohol intake and daytime napping. Adiposity
33 traits are the leading causal cardiometabolic risk factors for GrimAgeAccel and
34 PhenoAgeAccel, followed by type 2 diabetes, triglycerides, and C-reactive
35 protein.
- 36 • This study provides novel quantitative evidence on modifiable causal risk factors
37 for accelerated epigenetic ageing, indicating underlying contributors to the ageing
38 process and promising intervention targets to promote healthy longevity.

39 **Abstract**

40 **Background:** GrimAge acceleration (GrimAgeAccel) and PhenoAge acceleration

41 (PhenoAgeAccel) are DNA methylation-based markers of accelerated biological

42 ageing, standing out in predicting mortality and age-related cardiometabolic

43 morbidities. Causal risk factors for GrimAgeAccel and PhenoAgeAccel are unclear.

44 **Objective:** To evaluate causal associations of 18 common modifiable socioeconomic,

45 lifestyle, and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel.

46 **Methods:** We performed two-sample univariable and multivariable Mendelian

47 randomization (MR), using summary-level data for GrimAgeAccel and

48 PhenoAgeAccel derived from a genome-wide association study of 34,710 European

49 participants. We used the inverse-variance weighted method as the main analysis,

50 supplemented by three sensitivity analyses.

51 **Results:** Eleven and eight factors were causally associated with GrimAgeAccel and

52 PhenoAgeAccel, respectively. Smoking initiation was the strongest risk factor (β

53 [SE]: 1.299 [0.107] years) for GrimAgeAccel, followed by higher alcohol intake,

54 higher waist circumference, daytime napping, higher body fat percentage, higher

55 BMI, higher C-reactive protein, higher triglycerides, childhood obesity, and type 2

56 diabetes; whereas education was the strongest protective factor (β [SE] per 1-SD

57 increase in years of schooling: -1.143 [0.121] years). Higher waist circumference (β

58 [SE]: 0.850 [0.269] years) and education (β [SE]: -0.718 [0.151] years) were the

59 leading causal risk and protective factors for PhenoAgeAccel, respectively. Sensitivity

60 analyses strengthened the robustness of these causal associations, and the

61 multivariable MR analyses demonstrated independent direct effects of the strongest

62 risk and protective factors on GrimAgeAccel and PhenoAgeAccel, respectively.

63 **Conclusion:** Our findings provide novel quantitative evidence on modifiable causal

64 risk factors for epigenetic ageing, and hint at underlying contributors and intervention

65 targets to the ageing process.

66

67 **Keywords:** Epigenetic ageing; Education; Lifestyle behaviors; Cardiometabolic

68 traits; Mendelian randomization.

69 **Introduction**

70 Ageing involves the gradual accumulation of a decline in multiple biological
71 functions over time, leading to increased risks of developing age-related diseases and
72 mortality [1,2]. Although chronological ageing is uniform and unchangeable, the rate
73 of biological ageing is variable and modifiable depending on individual genetics,
74 environmental exposures, and health-related behaviors [3]. Of several potential types
75 of biological age predictors (e.g., epigenetic clock, leukocyte telomere length, and
76 transcriptomic predictors), the epigenetic clock that composed of DNA methylation at
77 multiple cytosine-phosphate-guanine (CpG) sites is currently the best one, as it
78 correlates well with age and predicts mortality across populations [4]. The epigenetic
79 age acceleration is the difference between chronological age and epigenetic age, and
80 represents accelerated biological ageing [5]. The second-generation epigenetic age
81 acceleration indicators, namely GrimAge acceleration (GrimAgeAccel) and
82 PhenoAge acceleration (PhenoAgeAccel), have been evolved to incorporate ageing-
83 related traits, and stand out in terms of predicting mortality and age-related
84 cardiometabolic morbidities [6-9].

85 Limited observational evidence has suggested that certain socioeconomic,
86 lifestyle behaviors, and cardiometabolic traits may be related to GrimAgeAccel and
87 PhenoAgeAccel [6,7,10,11]. Whether and to what extent modifiable risk factors
88 influence GrimAgeAccel and PhenoAgeAccel, if causally established, could shed
89 light on potential contributors to the ageing process and elucidate promising targets
90 for preventing age-related diseases and improving healthy longevity [12,13]. Thus far,
91 such causal evidence is scarce.

92 To fill this knowledge gap, we applied Mendelian randomization (MR) to
93 evaluate the causal associations of 18 common modifiable socioeconomic, lifestyle

94 and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel. The MR
95 method uses genetic variants as instrumental variables (IVs) to infer causality among
96 correlated traits. Since genetic variants are randomly allocated at conception, the MR
97 study is less susceptible to confounding and reverse causality than conventional
98 observational studies [14]. We conducted both univariable and multivariable MR
99 analyses to discern if modifiable factors have independent direct causal effects on
100 GrimAgeAccel and PhenoAgeAccel.

101

102 **Methods**

103 **Study design**

104 This MR study design is presented in **Figure 1**. We performed two-sample
105 univariable and multivariable MR strictly following the STROBE-MR guidelines
106 (**Supplementary Table 1**) [15]. To obtain unbiased estimates of the causal effects,
107 the MR analysis should adhere to three fundamental assumptions [16]: first, the IVs
108 are truly associated with the exposures; second, the IVs are independent of
109 confounders of the relationship between exposures and outcomes (GrimAgeAccel and
110 PhenoAgeAccel); third, the IVs influence the outcomes only through the exposures,
111 but not any direct or indirect pathways. All data used in this MR study are publicly
112 available. Ethical approval and informed consent had been obtained in all original
113 studies.

114

115 **Selection rationale and data sources of genetic instruments**

116 We selected 18 common modifiable factors, including educational attainment,
117 lifestyle behaviors (smoking initiation, alcohol intake, coffee consumption, daytime
118 napping, sleep duration, and moderate-to vigorous physical activity [MVPA]), and

119 cardiometabolic traits (body mass index [BMI], waist circumference, body fat
120 percentage [BF%], childhood obesity, type 2 diabetes, low-density lipoprotein [LDL]
121 cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, systolic blood
122 pressure [SBP], diastolic blood pressure [DBP], and C-reactive protein [CRP]).
123 Definitions of the 18 modifiable factors are shown in **Supplementary Table 2**.

124 We extracted genetic variants for each of the modifiable factors from the largest
125 available genome-wide association studies (GWASs) of European ancestry [17-29],
126 ensuring minimum sample overlap with the genetic variants for GrimAgeAccel and
127 PhenoAgeAccel (**Supplementary Table 3**). We included single nucleotide
128 polymorphisms (SNPs) robustly associated with the 18 modifiable factors at the
129 genome-wide significance ($P < 5 \times 10^{-8}$). To select independent genetic variants, a
130 stringent condition (linkage disequilibrium threshold of $r^2 < 0.01$) was set to minimize
131 the influence of linkage disequilibrium which may bias the results of randomized
132 allele allocation. Where SNPs for the exposures were not available in the GWAS
133 summary statistics of GrimAgeAccel or PhenoAgeAccel, we used proxies of SNPs
134 with $r^2 > 0.8$ as substitutes, by using the LDproxy search on the online platform
135 LDlink (<https://ldlink.nci.nih.gov/>) [30].

136

137 **Data source for epigenetic age acceleration**

138 The genetic associations with GrimAgeAccel and PhenoAgeAccel were extracted
139 from a recent GWAS meta-analysis (summary statistics available at
140 <https://datashare.is.ed.ac.uk/handle/10283/3645>), which included 34,710 European
141 participants from 28 cohorts [31]. GrimAgeAccel and PhenoAgeAccel are two-
142 generation epigenetic age acceleration indicators, expressing the biological ageing
143 rate in years, of which GrimAgeAccel is more strongly associated with mortality than

144 PhenoAgeAccel [11]. Detailed definitions of GrimAgeAccel and PhenoAgeAccel and
145 data preparation in GWAS are shown in **Supplementary Table 2**.

146

147 **Statistical analyses**

148 In the main analysis, we used the inverse-variance weighted (IVW) method to
149 determine MR causal estimates (β coefficients with standard errors [SEs]) for
150 associations of each modifiable factor with GrimAgeAccel and PhenoAgeAccel. The
151 IVW combined the Wald ratio estimates of every single SNP in the set of IVs into one
152 causal estimate using the random-effects meta-analysis approach [32]. To evaluate the
153 robustness of the IVW estimates under different assumptions and to detect possible
154 pleiotropy, we performed three sensitivity analyses, including the MR weighted
155 median, the MR Egger, and the MR pleiotropy residual sum and outlier (MR-
156 PRESSO) methods. The weighted median method selected the median MR estimate
157 as the causal estimate, and provided a consistent causal estimate if over 50% of the
158 weight in the analysis was derived from valid IVs [33]. The MR Egger method which
159 allowed the intercept to be freely estimated as an indicator of pleiotropy was used to
160 identify and adjust for the potential directional pleiotropic bias, but has limited
161 precision [34]. The MR-PRESSO method was applied to detect and correct for any
162 outlier SNP reflecting likely horizontal pleiotropic biases for MR causal estimates
163 [35]. We evaluated the heterogeneity for the IVW estimates using the Cochran's Q
164 test [36], and identified the horizontal pleiotropy based on the p-value for the intercept
165 in the MR-Egger model [34]. A false discovery rate (FDR) method was used to
166 correct results for multiple testing, and FDR q-values were provided. In this study,
167 strong causal evidence was defined as an association supported by the main analysis
168 (FDR q-value <0.05) and at least one sensitivity analysis. Suggestive causal evidence

169 was defined as a suggest association with $P < 0.05$ and FDR q value ≥ 0.05 in the main
170 analysis. Null causal evidence was defined as no statistically significant association
171 revealed from the main analysis ($P \geq 0.05$).

172 We further conducted multivariable MR (MVMR) analyses to assess whether the
173 causal effects of the strongest protective factor and the strongest risk factor on
174 GrimAgeAccel and PhenoAgeAccel were independent of other exposure factors [37].
175 Taking into account the effect size and significance of causal associations, we
176 selected exposure factors with β coefficients > 0.5 and $P < 0.05$ in the main analysis as
177 covariates in the adjustment models.

178 The two-sample MR analyses were conducted with the R packages
179 ‘*TwoSampleMR*’ and ‘*MRPRESSO*’ in R software (version 4.0.3). FDR q -values were
180 estimated using the R package ‘*fdrtool*’.

181

182 **Results**

183 **MR results for associations between 18 modifiable factors and GrimAgeAccel**

184 Ten out of the 18 risk factors showed strong associations with increased
185 GrimAgeAccel after FDR adjustment for multiple comparisons (**Table 1**). Smoking
186 initiation was the strongest risk factor (β [SE]: 1.299 [0.107] years) for
187 GrimAgeAccel, followed by higher alcohol intake (β [SE] per 1-SD increase: 0.899
188 [0.361] years), higher waist circumference (β [SE] per 1-SD increase: 0.815 [0.184]
189 years), daytime napping (β [SE]: 0.805 [0.355] years), higher BF% (β [SE] per 1-SD
190 increase: 0.748 [0.120] years), higher BMI (β [SE] per 1-SD increase: 0.592 [0.079]
191 years), higher CRP (β [SE] per 1-SD increase: 0.345 [0.073] years), higher
192 triglycerides (β [SE] per 1-SD increase: 0.249 [0.091] years), childhood obesity (β
193 [SE]: 0.200 [0.075] years), and type 2 diabetes (β [SE]: 0.095 [0.041] years); **Figure**

194 **2a).** By contrast, educational attainment in years of schooling was the only one
195 protective factor associated with decreased GrimAgeAccel (β [SE] per 1-SD increase:
196 -1.143 [0.121] years). There was little evidence to support a causal association of
197 other modifiable factors with GrimAgeAccel.

198 Associations of the above 11 modifiable factors with GrimAgeAccel were robust
199 across sensitivity analyses with consistent effect directions and $P < 0.05$ in at least one
200 sensitivity analysis. The MR-Egger intercept tests indicated potential pleiotropy for
201 CRP ($P_{\text{intercept}} < 0.05$; **Supplementary Table 4**). Cochran's Q-test showed possible
202 heterogeneity for educational attainment, alcohol intake, BMI, BF%, type 2 diabetes,
203 LDL cholesterol, HDL cholesterol, and CRP ($P_h < 0.05$; **Supplementary Table 4**).
204 However, with the exclusion of outlying SNPs, the MR-PRESSO analysis showed
205 consistent results with the IVW analysis (**Table 1**).

206

207 **MR results for associations between 18 modifiable factors and PhenoAgeAccel**

208 Eight modifiable factors showed strong associations with PhenoAgeAccel after FDR
209 adjustment for multiple comparisons (**Table 2**). Higher waist circumference was the
210 strongest risk factor (β [SE] per 1-SD increase: 0.850 [0.269] years) for
211 PhenoAgeAccel, followed by higher BF% (β [SE] per 1-SD increase: 0.711 [0.152]
212 years), higher BMI (β [SE] per 1-SD increase: 0.586 [0.102] years), smoking
213 initiation (β [SE]: 0.519 [0.142] years), higher CRP (β [SE] per 1-SD increase: 0.349
214 [0.095] years), childhood obesity (β [SE]: 0.229 [0.095] years), and type 2 diabetes (β
215 [SE]: 0.125 [0.051] years). Whereas the genetically predicted higher educational
216 attainment in years of schooling was associated with decreased PhenoAgeAccel (β
217 [SE] per 1-SD increase: -0.718 [0.151] years; **Figure 2b**). Suggestive causality was
218 identified for the association between genetically predicted higher DBP and increased

219 PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.049 [0.024] years). No significant
220 association was observed with PhenoAgeAccel for the other modifiable factors.

221 Associations for the above eight modifiable factors were robust in sensitivity
222 analyses with consistent effect directions and $P < 0.05$ in at least one sensitivity
223 analysis. There was no evidence of pleiotropy for these risk factors except for CRP
224 ($P_{\text{intercept}} < 0.05$; **Supplementary Table 5**). Potential heterogeneity was observed for
225 educational attainment, smoking initiation, BMI, waist circumference, BF%, type 2
226 diabetes, and CRP ($P_h < 0.05$). One to four outliers were detected in the MR-PRESSO
227 analyses; however, the associations remained consistent after removal of these
228 outliers (**Table 2**). For SBP, with excluding the outlying SNP rs62523863, the MR-
229 PRESSO analysis revealed a potentially positive association between genetically
230 predicted higher SBP and PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.038
231 [0.016] years).

232

233 **MVMR results for associations of the strongest protective and risk factors with** 234 **GrimAgeAccel and PhenoAgeAccel**

235 In MVMR analyses, the association between educational attainment (the strongest
236 protective factor) and GrimAgeAccel remained significant with adjustment for
237 smoking initiation, alcohol intake, waist circumference, daytime napping, BF%, or
238 BMI (**Figure 3a**). Likewise, the significant association between smoking initiation
239 (the strongest risk factor) and GrimAgeAccel persisted after adjustment for education,
240 alcohol intake, waist circumference, daytime napping, BF%, or BMI. All covariates in
241 MVMR analyses were selected based on their considerable effects on GrimAgeAccel
242 in terms of size (β coefficients > 0.5) and significance ($P < 0.05$ in the main analysis).

243 The associations of education (the strongest protective factor) and waist
244 circumference (the strongest risk factor) with PhenoAgeAccel remained significant
245 with adjustment for waist circumference, BF%, BMI, or smoking initiation, which
246 had considerable causal effects on PhenoAgeAccel (β coefficients >0.5 ; **Figure 3b**).

247

248 **Discussion**

249 This MR study for the first time delineated potential causal relationships of 18
250 common modifiable factors with GrimAgeAccel and PhenoAgeAccel, the robust
251 second-generation epigenetic age acceleration indicators. We identified strong
252 evidence for 11 and eight factors associated with GrimAgeAccel and PhenoAgeAccel,
253 respectively. Smoking initiation exhibited the greatest effect on increased
254 GrimAgeAccel (1.299 years), followed by higher alcohol intake, higher waist
255 circumference, daytime napping, higher BF%, higher BMI, higher CRP, higher
256 triglycerides, childhood obesity, and type 2 diabetes; whereas educational attainment
257 showed the greatest effect on decreased GrimAgeAccel (-1.143 years per 1-SD
258 increase in years of schooling). Higher waist circumference and educational
259 attainment were the leading causal risk and protective factors associated with
260 PhenoAgeAccel, respectively; BF%, BMI, smoking initiation, CRP, childhood
261 obesity, and type 2 diabetes were also associated with increased PhenoAgeAccel.
262 Multiple sensitivity analyses further strengthened the robustness of these causal
263 relationships, and the MVMR analyses demonstrated the independent direct effects of
264 the strongest risk and protective factors on GrimAgeAccel and PhenoAgeAccel,
265 respectively. Suggestive causality was identified for the association between higher
266 DBP and increased PhenoAgeAccel.

267 In this study, educational attainment was the major protective factor for both
268 GrimAgeAccel and PhenoAgeAccel, and this causal effect was largely independent of
269 other causal factors, such as smoking and adiposity-related traits. Educational
270 attainment is a strong proxy for socioeconomic status and a more upstream
271 determinant of health, with broad implications for a person's life-long lifestyle
272 behaviors and health-promoting resources [38]. A recent study using UK Biobank
273 data has documented that each 1-year increase in genetically determined educational
274 attainment was associated with equivalently 4.2 years of age-related increases in
275 telomere length [39]. Telomere length and epigenetic age acceleration metrics (e.g.,
276 GrimAgeAccel and PhenoAgeAccel) point towards distinct mechanisms of the ageing
277 process that are marked by telomeres and the DNA methylation-based epigenetic
278 clocks, both of which are independently associated with chronological age and
279 mortality risk [40]. Our findings, together with those of the UK Biobank, highlight the
280 important impact of educational attainment on biological ageing rates from two
281 different aspects of the ageing process. Therefore, public health strategies aimed at
282 reducing educational inequalities and improving educational attainment may slow the
283 biological ageing rate and help reduce age-related health burdens.

284 This MR study identified several common lifestyle behaviors, including smoking
285 initiation, alcohol intake, and daytime napping, causally associated with increased
286 GrimAgeAccel or PhenoAgeAccel (smoking initiation only), which were consistent
287 with previous evidence from observational studies [6,7]. Smoking methylation proxy
288 is a component of the GrimAge clock [7], thus it is not surprising that smoking
289 initiation exhibited a large effect on increased GrimAgeAccel in this study, and the
290 MVMR analysis further confirmed that the effect of smoking on GrimAgeAccel was
291 independent of other causal lifestyle behaviors and adiposity-related traits. Similarly,

292 genetically determined smoking has been associated with shorter telomere length in
293 the UK Biobank [41], and evidence from the Danish Health Interview Survey
294 suggested that the life expectancy of a heavy smoker was a little more than seven
295 years shorter than that of a never smoker [42]. Our study also provided strong MR
296 evidence that genetically predicted higher alcohol intake was associated with
297 increased GrimAgeAccel. A study composed of the Hannum cohort and Family and
298 Community Health Studies cohort found that the relationship between alcohol use and
299 the first-generation epigenetic clocks seemed to be nonlinear [42]. However, given the
300 dose-dependent relationship of alcohol intake with all-cause mortality and cancers
301 [43], our findings suggest that reducing alcohol intake is necessary to decrease
302 GrimAgeAccel and retard the overall health loss. Previous observational studies also
303 reported positive or inverse correlations of other lifestyle behaviors such as MVPA,
304 coffee, and sleep duration with GrimAgeAccel, PhenoAgeAccel, or mortality
305 [11,44,45]. Nevertheless, in this study, there was little evidence supporting these
306 associations were causal. The discrepancy between our findings and previous
307 observations may result from the potential confounding or reverse causation in
308 conventional observational studies. Moreover, the non-linear association patterns, as
309 in the case of sleep duration and mortality, might also partially explain the
310 inconsistent results [46]. Therefore, our null findings should be cautiously interpreted.

311 Interestingly, of all cardiometabolic traits (i.e., adiposity traits, type 2 diabetes,
312 triglycerides, and CRP) which causally increased GrimAgeAccel or PhenoAgeAccel,
313 adiposity traits were the most dominant traits. Emerging observational studies have
314 pronounced the positive associations of BMI with GrimAgeAccel and
315 PhenoAgeAccel [11], and a meta-analysis of 87 observational studies showed each 5-
316 kg/m² higher BMI corresponded to about 1 year of age-related decrease in telomere

317 length [46]. Our study further provided strong evidence for causal associations of
318 various adiposity phenotypes, including waist circumference, BF%, BMI, and
319 childhood obesity, with increased GrimAgeAccel and PhenoAgeAccel. In this study,
320 type 2 diabetes, triglycerides, and CRP showed strong but modest effects (β
321 coefficients ≤ 0.5) on GrimAgeAccel or PhenoAgeAccel, which was consistent with
322 the findings of the UK Biobank study on telomere length [39].

323 This MR study yields new insights into modifiable causal factors, including
324 education, lifestyle behaviors, and cardiometabolic traits, associated with accelerating
325 or decelerating epigenetic ageing. This study brings us one step closer to
326 understanding the potential contributors to the ageing process and provides promising
327 intervention targets for healthy ageing. Given the enormous burden induced by age-
328 related morbidity and mortality, strategies to reduce educational inequalities, promote
329 healthy lifestyles primarily through reducing smoking, alcohol intake, and daytime
330 napping, and improve cardiometabolic traits, specifically adiposity, type 2 diabetes,
331 triglycerides, and CRP, to slow biological ageing rate are imminent.

332 In this study, we included independent and genome-wide significant SNPs as
333 instruments for each of the modifiable factors to ensure the first MR assumption was
334 fulfilled. Moreover, we applied strict criteria strengthened by the FDR-corrected
335 significance and the cross-validations by main and sensitivity analyses to draw robust
336 causal conclusions. However, several limitations merited consideration. First, we
337 found potential pleiotropy from the MR-Egger intercept test for CRP. However, we
338 conducted MR-PRESSO analysis, and the association remained consistent after
339 removal of outlying SNPs. Second, we could not rule out the possibility that the
340 associations of certain modifiable risk factors such as alcohol intake and sleep
341 duration with GrimAgeAccel or PhenoAgeAccel may be non-linear. Future studies

342 with individual-level data are warranted to confirm the linear or non-linear
343 relationships. Third, to ensure the consistency of genetic background, this MR study
344 was performed only in European-ancestry participants, thus the generalization of our
345 results to other ethnic groups should be cautious.

346

347 **Conclusions**

348 This MR study provided novel quantitative evidence on modifiable causal
349 socioeconomic, lifestyle, and cardiometabolic factors for accelerated epigenetic
350 ageing. Our findings shed light on the underlying contributors to the biological ageing
351 process and point toward promising intervention targets to slow the biological ageing
352 rate and promote healthy longevity.

353 **List of abbreviations**

| | |
|---------------|--|
| BF% | Body fat percentage |
| BMI | Body mass index |
| CI | Confidence interval |
| CpG | Cytosine-phosphate-guanine |
| CRP | C-reactive protein |
| DBP | Diastolic blood pressure |
| FDR | False discovery rate |
| GrimAgeAccel | GrimAge acceleration |
| GWAS | Genome-wide association study |
| HDL | High-density lipoprotein |
| IV | Instrumental variable |
| IVW | Inverse variance weighted |
| LDL | Low-density lipoprotein |
| MVPA | Moderate-to vigorous physical activity |
| MR | Mendelian randomization |
| MVMR | Multivariable Mendelian randomization |
| PhenoAgeAccel | PhenoAge acceleration |
| PRESSO | Pleiotropy residual sum and outlier |
| SBP | Systolic blood pressure |
| SD | Standard deviation |
| SE | Standard errors |
| SNP | Single nucleotide polymorphism |
| WM | Weighted median |

354

355 **Conflict-of-interest statement**

356 The authors declare that they have no competing interests.

357

358 **Ethics committee approval**

359 This study is based on publicly available summarized data. Ethical approval and
360 informed consent had been obtained in all original studies.

361

362 **Availability of data and materials**

363 The genetic association data of the 18 modifiable factors are available in
364 Supplementary Table 3. The GWAS summary statistics for GrimAgeAccel and
365 PhenoAgeAccel are available at <https://datashare.is.ed.ac.uk/handle/10283/3645>. The
366 analytical script of the MR analyses conducted in this study is available via the
367 GitHub repository of the “TwoSampleMR” R package
368 (<https://github.com/MRCIEU/TwoSampleMR/>).

369

370 **Funding**

371 This work was supported by the grants from the National Natural Science Foundation
372 of China (82022011, 81970706, 81730023, 82088102, 81970728, 81941017), the
373 Chinese Academy of Medical Sciences (2018PT32017, 2019PT330006), the
374 “Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant
375 Support” from Shanghai Jiao Tong University School of Medicine (20171901 Round
376 2), the Shanghai Shenkang Hospital Development Center (SHDC12019101,
377 SHDC2020CR1001A, SHDC2020CR3064B), the Shanghai Jiao Tong University
378 School of Medicine (DLY201801), and the Ruijin Hospital (2018CR002).

379

380 **Authors' contributions**

381 LK and TW contributed to the conception and design of the study. LK and CY
382 contributed to statistical analysis. LK contributed to drafting of the manuscript. TW
383 guaranteed this work and take responsibility for the integrity of the data. All authors
384 contributed to acquisition or interpretation of data, critical revision of the manuscript
385 for important intellectual content, and final approval of the version to be published.

386

387 **Acknowledgements**

388 We gratefully acknowledge the investigators and participants of all genome-wide
389 association studies from which we used data.

390 **References**

- 391 1. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol*.
392 2012;22(17):R741-R52.
- 393 2. Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage
394 in the ageing process. *Nature*. 2021;592(7856):695-703.
- 395 3. Warner HR. Current status of efforts to measure and modulate the biological rate of
396 aging. *J Gerontol A Biol Sci Med Sci*. 2004;59(7):692-6.
- 397 4. Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. *EBioMedicine*.
398 2017;21:29-36.
- 399 5. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock
400 theory of ageing. *Nat Rev Genet*. 2018;19(6):371-84.
- 401 6. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An
402 epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*.
403 2018;10(4):573-91.
- 404 7. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation
405 GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)*.
406 2019;11(2):303-27.
- 407 8. Wang C, Ni W, Yao Y, et al. DNA methylation-based biomarkers of age
408 acceleration and all-cause death, myocardial infarction, stroke, and cancer in two
409 cohorts: The NAS, and KORA F4. *EBioMedicine*. 2021;63:103151.
- 410 9. Li A, Koch Z, Ideker T. Epigenetic aging: Biological age prediction and informing
411 a mechanistic theory of aging [published online ahead of print, 2022 Jun 20]. *J Intern*

412 *Med.*

413 10. Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic
414 clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY)*.
415 2017;9(2):419-46.

416 11. Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic
417 review of biological, social and environmental factors associated with epigenetic
418 clock acceleration. *Ageing Res Rev*. 2021;69:101348.

419 12. Sierra F, Caspi A, Fortinsky RH, Haynes L, Lithgow GJ, Moffitt TE, et al. Moving
420 geroscience from the bench to clinical care and health policy. *J Am Geriatr Soc*.
421 2021;69(9):2455-63.

422 13. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From
423 discoveries in ageing research to therapeutics for healthy ageing. *Nature*.
424 2019;571(7764):183-92.

425 14. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
426 studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.

427 15. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA,
428 VanderWeele TJ, et al. Strengthening the reporting of observational studies in
429 epidemiology using mendelian randomisation (STROBE-MR): explanation and
430 elaboration. *BMJ*. 2021;375:n2233.

431 16. Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent
432 Developments in Mendelian Randomization Studies. *Curr Epidemiol Rep*.
433 2017;4(4):330-45.

- 434 17. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a
435 genome-wide association study of educational attainment in 1.1 million individuals.
436 *Nat Genet.* 2018;50(8):1112-1121.
- 437 18. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million
438 individuals yield new insights into the genetic etiology of tobacco and alcohol use.
439 *Nat Genet.* 2019;51(2):237-244.
- 440 19. Zhong VW, Kuang A, Danning RD, et al. A genome-wide association study of
441 bitter and sweet beverage consumption [published correction appears in *Hum Mol*
442 *Genet.* 2019 May 02;:]. *Hum Mol Genet.* 2019;28(14):2449-2457.
- 443 20. Dashti HS, Daghlas I, Lane JM, et al. Genetic determinants of daytime napping
444 and effects on cardiometabolic health. *Nat Commun.* 2021;12(1):900.
- 445 21. Dashti HS, Jones SE, Wood AR, et al. Genome-wide association study identifies
446 genetic loci for self-reported habitual sleep duration supported by accelerometer-
447 derived estimates. *Nat Commun.* 2019;10(1):1100.
- 448 22. Klimentidis YC, Raichlen DA, Bea J, et al. Genome-wide association study of
449 habitual physical activity in over 377,000 UK Biobank participants identifies multiple
450 variants including *CADM2* and *APOE*. *Int J Obes (Lond).* 2018;42(6):1161-1176.
- 451 23. Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide
452 association studies for height and body mass index in ~700000 individuals of
453 European ancestry. *Hum Mol Genet.* 2018;27(20):3641-3649.
- 454 24. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose
455 and insulin biology to body fat distribution. *Nature.* 2015;518(7538):187-196.

- 456 25. Bradfield JP, Taal HR, Timpson NJ, et al. A genome-wide association meta-
457 analysis identifies new childhood obesity loci. *Nat Genet.* 2012;44(5):526-531.
- 458 26. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to
459 single-variant resolution using high-density imputation and islet-specific epigenome
460 maps. *Nat Genet.* 2018;50(11):1505-1513.
- 461 27. Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000
462 multi-ethnic participants of the Million Veteran Program. *Nat Genet.*
463 2018;50(11):1514-1523.
- 464 28. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1
465 million people identifies 535 new loci associated with blood pressure traits [published
466 correction appears in *Nat Genet.* 2018 Dec;50(12):1755]. *Nat Genet.*
467 2018;50(10):1412-1425.
- 468 29. Han X, Ong JS, An J, Hewitt AW, Gharahkhani P, MacGregor S. Using Mendelian
469 randomization to evaluate the causal relationship between serum C-reactive protein
470 levels and age-related macular degeneration. *Eur J Epidemiol.* 2020;35(2):139-146.
- 471 30. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring
472 population-specific haplotype structure and linking correlated alleles of possible
473 functional variants. *Bioinformatics.* 2015;31(21):3555-7.
- 474 31. McCartney DL, Min JL, Richmond RC, Lu AT, Sobczyk MK, Davies G, et al.
475 Genome-wide association studies identify 137 genetic loci for DNA methylation
476 biomarkers of aging. *Genome Biol.* 2021;22(1):194.
- 477 32. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian

- 478 randomization: using genes as instruments for making causal inferences in
479 epidemiology. *Stat Med.* 2008;27(8):1133-1163.
- 480 33. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
481 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
482 Estimator. *Genet Epidemiol.* 2016;40(4):304-314.
- 483 34. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for
484 Robust Causal Inference from Mendelian Randomization Analyses with Multiple
485 Genetic Variants. *Epidemiology (Cambridge, Mass).* 2017;28(1):30-42.
- 486 35. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
487 pleiotropy in causal relationships inferred from Mendelian randomization between
488 complex traits and diseases. *Nat Genet.* 2018;50(5):693-8.
- 489 36. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A
490 framework for the investigation of pleiotropy in two-sample summary data Mendelian
491 randomization. *Stat Med.* 2017;36(11):1783-802.
- 492 37. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of
493 pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol.*
494 2015;181(4):251-260.
- 495 38. Figgins E, Pieruccini-Faria F, Speechley M, Montero-Odasso M. Potentially
496 modifiable risk factors for slow gait in community-dwelling older adults: A systematic
497 review. *Ageing Res Rev.* 2021;66:101253.
- 498 39. Bountziouka V, Musicha C, Allara E, et al. Modifiable traits, healthy behaviours,
499 and leukocyte telomere length: a population-based study in UK Biobank. *Lancet*

500 *Healthy Longev.* 2022;3(5):e321-e331.

501 40. Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length

502 are independently associated with chronological age and mortality [published

503 correction appears in *Int J Epidemiol.* 2018 Feb 1;47(1):356]. *Int J Epidemiol.*

504 2018;45(2):424-432.

505 41. Brønnum-Hansen H, Juel K. Abstinence from smoking extends life and

506 compresses morbidity: a population based study of health expectancy among smokers

507 and never smokers in Denmark. *Tob Control.* 2001;10(3):273-278.

508 42. Beach SR, Dogan MV, Lei MK, et al. Methyloomic Aging as a Window onto the

509 Influence of Lifestyle: Tobacco and Alcohol Use Alter the Rate of Biological Aging. *J*

510 *Am Geriatr Soc.* 2015;63(12):2519-2525.

511 43. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease

512 attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a

513 systematic analysis for the Global Burden of Disease Study 2016 [published

514 correction appears in *Lancet Psychiatry.* 2019 Jan;6(1):e2]. *Lancet Psychiatry.*

515 2018;5(12):987-1012.

516 44. Loftfield E, Cornelis MC, Caporaso N, Yu K, Sinha R, Freedman N. Association

517 of Coffee Drinking With Mortality by Genetic Variation in Caffeine Metabolism:

518 Findings From the UK Biobank. *JAMA Intern Med.* 2018;178(8):1086-1097.

519 45. Wang C, Bangdiwala SI, Rangarajan S, et al. Association of estimated sleep

520 duration and naps with mortality and cardiovascular events: a study of 116 632 people

521 from 21 countries. *Eur Heart J.* 2019;40(20):1620-1629.

- 522 46. Gielen M, Hageman GJ, Antoniou EE, et al. Body mass index is negatively
523 associated with telomere length: a collaborative cross-sectional meta-analysis of 87
524 observational studies. *Am J Clin Nutr*. 2018;108(3):453-475.

Table 1. MR results of the associations between 18 modifiable factors and GrimAgeAccel

| Modifiable factor | No. of SNP | Main analysis | | | Sensitivity analyses | | | | | | | | | |
|------------------------------|------------|-----------------------|-----------------|----------|-----------------------|-----------------|----------|----------------------|--------------|---------|----------------|-----------------------|-----------------|----------|
| | | IVW | | | Weighted median | | | MR-Egger | | | MR-PRESSO | | | |
| | | β (SE) | P value | q value | β (SE) | P value | q value | β (SE) | P value | q value | No. of outlier | β (SE) | P value | q value |
| Socioeconomic factor | | | | | | | | | | | | | | |
| Educational attainment | 751 | -1.143 (0.121) | 3.31E-21 | 2.98E-20 | -1.129 (0.172) | 5.47E-11 | 4.92E-10 | -0.829 (0.452) | 0.067 | 0.277 | 4 | -1.116 (0.116) | 6.54E-21 | 5.89E-20 |
| Lifestyle behavior | | | | | | | | | | | | | | |
| Smoking initiation | 299 | 1.299 (0.107) | 4.90E-34 | 8.82E-33 | 1.257 (0.157) | 1.42E-15 | 2.56E-14 | 1.321 (0.446) | 0.003 | 0.027 | 0 | 1.276 (0.103) | 7.63E-29 | 1.37E-27 |
| Alcohol intake | 80 | 0.899 (0.361) | 0.013 | 0.026 | 0.380 (0.567) | 0.502 | 0.602 | 0.481 (0.738) | 0.516 | 0.771 | 0 | 0.967 (0.357) | 0.008 | 0.018 |
| Coffee consumption | 12 | 0.003 (0.005) | 0.589 | 0.624 | -0.003 (0.006) | 0.615 | 0.692 | -0.008 (0.010) | 0.464 | 0.771 | 0 | 0.003 (0.005) | 0.600 | 0.635 |
| Sleep | | | | | | | | | | | | | | |
| Daytime napping | 115 | 0.805 (0.355) | 0.023 | 0.038 | 0.524 (0.514) | 0.308 | 0.449 | 0.411 (1.235) | 0.740 | 0.833 | 0 | 0.813 (0.346) | 0.020 | 0.033 |
| Sleep duration | 77 | -0.301 (0.266) | 0.257 | 0.356 | -0.403 (0.400) | 0.313 | 0.449 | -0.077 (1.017) | 0.940 | 0.940 | 0 | -0.275 (0.261) | 0.294 | 0.378 |
| MVPA | 6 | -0.186 (0.903) | 0.837 | 0.837 | -0.036 (1.198) | 0.976 | 0.976 | -9.279 (5.557) | 0.170 | 0.510 | 0 | -0.186 (0.763) | 0.817 | 0.817 |
| Cardiometabolic trait | | | | | | | | | | | | | | |
| Adiposity | | | | | | | | | | | | | | |
| BMI | 941 | 0.592 (0.079) | 9.16E-14 | 5.50E-13 | 0.490 (0.124) | 7.92E-05 | 3.56E-04 | 0.790 (0.231) | 0.001 | 0.018 | 2 | 0.595 (0.078) | 6.30E-14 | 3.78E-13 |
| Waist circumference | 44 | 0.815 (0.184) | 9.26E-06 | 2.78E-05 | 0.776 (0.272) | 0.004 | 0.014 | 0.913 (0.504) | 0.077 | 0.277 | 0 | 0.815 (0.184) | 6.31E-05 | 1.89E-04 |
| BF% | 641 | 0.748 (0.120) | 4.12E-10 | 1.85E-09 | 0.740 (0.182) | 4.87E-05 | 2.92E-04 | 0.843 (0.400) | 0.036 | 0.216 | 3 | 0.796 (0.115) | 1.19E-11 | 5.36E-11 |
| Childhood obesity | 5 | 0.200 (0.075) | 0.007 | 0.016 | 0.142 (0.098) | 0.146 | 0.292 | 0.789 (0.554) | 0.249 | 0.560 | 0 | 0.204 (0.057) | 0.016 | 0.029 |
| Type 2 diabetes | 232 | 0.095 (0.041) | 0.020 | 0.036 | 0.084 (0.071) | 0.236 | 0.425 | 0.043 (0.092) | 0.644 | 0.773 | 0 | 0.100 (0.040) | 0.013 | 0.026 |
| Lipids | | | | | | | | | | | | | | |
| LDL cholesterol | 145 | -0.094 (0.096) | 0.327 | 0.392 | -0.064 (0.163) | 0.695 | 0.736 | 0.016 (0.142) | 0.908 | 0.940 | 1 | -0.069 (0.094) | 0.463 | 0.542 |
| HDL cholesterol | 223 | -0.181 (0.095) | 0.056 | 0.084 | -0.267 (0.138) | 0.053 | 0.136 | -0.078 (0.162) | 0.632 | 0.773 | 2 | -0.175 (0.090) | 0.054 | 0.081 |
| Triglycerides | 173 | 0.249 (0.091) | 0.006 | 0.015 | 0.239 (0.144) | 0.096 | 0.216 | 0.152 (0.152) | 0.319 | 0.638 | 0 | 0.254 (0.091) | 0.006 | 0.015 |
| Blood pressure | | | | | | | | | | | | | | |
| SBP | 222 | 0.013 (0.012) | 0.279 | 0.359 | 0.015 (0.018) | 0.421 | 0.541 | 0.029 (0.049) | 0.557 | 0.771 | 0 | 0.013 (0.012) | 0.282 | 0.378 |
| DBP | 264 | 0.011 (0.019) | 0.565 | 0.624 | 0.027 (0.027) | 0.324 | 0.449 | 0.083 (0.066) | 0.213 | 0.548 | 0 | 0.013 (0.018) | 0.482 | 0.542 |
| CRP | 299 | 0.345 (0.073) | 2.31E-06 | 8.32E-06 | 0.245 (0.107) | 0.022 | 0.066 | 0.060 (0.100) | 0.553 | 0.771 | 1 | 0.348 (0.071) | 1.64E-06 | 5.90E-06 |

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock. The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with GrimAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism.

Table 2. MR results of the associations between 18 modifiable factors and PhenoAgeAccel

| Modifiable factor | No. of SNP | Main analysis | | | Sensitivity analyses | | | | | | | | | |
|------------------------------|------------|-----------------------|-----------------|----------|-----------------------|-----------------|---------|----------------------|--------------|---------|----------------|-----------------------|-----------------|----------|
| | | IVW | | | Weighted median | | | MR-Egger | | | MR-PRESSO | | | |
| | | β (SE) | P value | q value | β (SE) | P value | q value | β (SE) | P value | q value | No. of outlier | β (SE) | P value | q value |
| Socioeconomic factor | | | | | | | | | | | | | | |
| Educational attainment | 751 | -0.718 (0.151) | 1.83E-06 | 1.65E-05 | -0.633 (0.225) | 0.005 | 0.030 | -0.361 (0.565) | 0.523 | 0.930 | 3 | -0.689 (0.145) | 2.52E-06 | 2.27E-05 |
| Lifestyle behavior | | | | | | | | | | | | | | |
| Smoking initiation | 299 | 0.519 (0.142) | 2.43E-04 | 0.001 | 0.404 (0.205) | 0.049 | 0.221 | 1.222 (0.589) | 0.039 | 0.240 | 1 | 0.545 (0.135) | 7.20E-05 | 3.24E-04 |
| Alcohol intake | 80 | 0.669 (0.441) | 0.130 | 0.213 | 1.134 (0.656) | 0.084 | 0.252 | 1.693 (0.923) | 0.070 | 0.252 | 0 | 0.737 (0.432) | 0.092 | 0.151 |
| Coffee consumption | 12 | 0.004 (0.008) | 0.600 | 0.735 | 0.002 (0.007) | 0.773 | 0.991 | -0.003 (0.015) | 0.861 | 0.930 | 0 | 0.004 (0.008) | 0.610 | 0.705 |
| Sleep | | | | | | | | | | | | | | |
| Daytime napping | 115 | 0.115 (0.500) | 0.818 | 0.818 | 0.014 (0.665) | 0.984 | 0.991 | 0.152 (1.742) | 0.931 | 0.931 | 0 | 0.083 (0.488) | 0.866 | 0.866 |
| Sleep duration | 77 | -0.472 (0.357) | 0.187 | 0.281 | -0.526 (0.462) | 0.255 | 0.417 | 2.771 (1.324) | 0.040 | 0.240 | 0 | -0.319 (0.357) | 0.375 | 0.519 |
| MVPA | 6 | 0.368 (1.138) | 0.747 | 0.791 | 0.262 (1.347) | 0.846 | 0.991 | -2.565 (6.947) | 0.731 | 0.930 | 0 | 0.368 (0.649) | 0.596 | 0.705 |
| Cardiometabolic trait | | | | | | | | | | | | | | |
| Adiposity | | | | | | | | | | | | | | |
| BMI | 941 | 0.586 (0.102) | 1.08E-08 | 1.94E-07 | 0.680 (0.170) | 6.33E-05 | 0.001 | 0.510 (0.298) | 0.087 | 0.261 | 4 | 0.605 (0.099) | 1.53E-09 | 2.75E-08 |
| Waist circumference | 44 | 0.850 (0.269) | 0.002 | 0.006 | 0.632 (0.339) | 0.062 | 0.223 | 0.739 (0.740) | 0.324 | 0.704 | 1 | 0.771 (0.249) | 0.003 | 0.009 |
| BF% | 641 | 0.711 (0.152) | 2.88E-06 | 1.73E-05 | 0.734 (0.227) | 0.001 | 0.009 | 1.666 (0.509) | 0.001 | 0.018 | 4 | 0.664 (0.145) | 5.75E-06 | 3.45E-05 |
| Childhood obesity | 5 | 0.229 (0.095) | 0.016 | 0.036 | 0.154 (0.123) | 0.211 | 0.380 | 0.140 (0.724) | 0.859 | 0.930 | 0 | 0.223 (0.071) | 0.025 | 0.050 |
| Type 2 diabetes | 232 | 0.125 (0.051) | 0.014 | 0.036 | 0.102 (0.080) | 0.205 | 0.380 | 0.056 (0.116) | 0.628 | 0.930 | 0 | 0.120 (0.049) | 0.016 | 0.036 |
| Lipids | | | | | | | | | | | | | | |
| LDL cholesterol | 145 | 0.055 (0.123) | 0.653 | 0.735 | -0.002 (0.174) | 0.991 | 0.991 | 0.169 (0.181) | 0.352 | 0.704 | 1 | 0.059 (0.123) | 0.633 | 0.705 |
| HDL cholesterol | 223 | -0.127 (0.109) | 0.243 | 0.336 | 0.068 (0.166) | 0.684 | 0.947 | 0.103 (0.187) | 0.583 | 0.930 | 0 | -0.121 (0.109) | 0.267 | 0.401 |
| Triglycerides | 173 | -0.058 (0.121) | 0.635 | 0.735 | 0.009 (0.196) | 0.964 | 0.991 | -0.202 (0.203) | 0.320 | 0.704 | 0 | -0.052 (0.121) | 0.666 | 0.705 |
| Blood pressure | | | | | | | | | | | | | | |
| SBP | 222 | 0.032 (0.016) | 0.053 | 0.095 | 0.033 (0.023) | 0.149 | 0.338 | -0.013 (0.065) | 0.840 | 0.930 | 1 | 0.038 (0.016) | 0.015 | 0.036 |
| DBP | 264 | 0.049 (0.024) | 0.037 | 0.074 | 0.048 (0.034) | 0.150 | 0.338 | 0.161 (0.084) | 0.055 | 0.248 | 0 | 0.042 (0.023) | 0.069 | 0.124 |
| CRP | 298 | 0.349 (0.095) | 2.49E-04 | 0.001 | 0.061 (0.150) | 0.684 | 0.947 | 0.020 (0.132) | 0.878 | 0.930 | 1 | 0.362 (0.093) | 1.16E-04 | 4.18E-04 |

PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with PhenoAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism

Figure 1. Study design and assumptions of the MR analysis

Assumption 1 indicates that the genetic variants proposed as instrumental variables should be robustly associated with the exposures; assumption 2 indicates that the used instrumental variables should not be associated with potential confounders of the relationship between exposures and outcomes; and assumption 3 indicates that the selected instrumental variables should influence the outcomes only through the exposures, not via alternative pathways.

Abbreviations: GrimAgeAccel=epigenetic-age acceleration obtained using the GrimAge clock; HDL=high-density lipoprotein; LDL=low-density lipoprotein; MR=mendelian randomization; PhenoAgeAccel=epigenetic-age acceleration obtained using the PhenoAge clock; PRESSO=pleiotropy residual sum and outlier.




Figure 2. Overview of the findings on associations of 18 modifiable factors with GrimAgeAccel and PhenoAgeAccel

a. Causal associations between 18 modifiable factors and GrimAgeAccel; b. Causal associations between 18 modifiable factors and PhenoAgeAccel.

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock; PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; β represents the effect of each modifiable factor on epigenetic-age acceleration. Red box indicates a strong association with p value <0.05 and FDR q value <0.05 . Blue box indicates a suggestive association with p value <0.05 and FDR q value ≥ 0.05 . Grey box indicates null association with p value ≥ 0.05 . The IVW method was used for the main analysis. Sensitivity analyses included the MR-PRESSO, the MR-WM, and the MR-Egger methods.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=inverse-variance weighted; LDL=low-density lipoprotein; MR=mendelian randomization; MVPA=moderate to vigorous physical activity; PRESSO=pleiotropy residual sum and outlier; SBP=systolic blood pressure; SD=standard deviation; WM=weighted median.




Figure 3. Multivariable MR assessing the effects of the strongest protective factor and risk factor on GrimAgeAccel and PhenoAgeAccel

a. Effect of the strongest protective factor and risk factor on GrimAgeAccel; b. Effect of the strongest protective factor and risk factor on PhenoAgeAccel.

Causal estimates are β (95% CI) in years. Exposure factors with β coefficients >0.5 and $P < 0.05$ in the main analysis as shown in Figure 2 were selected as covariates in the adjustment models.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CI=confidence intervals; MR=mendelian randomization.

